Literature DB >> 17361330

Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells.

Steven De Vleeschouwer1, Isabel Spencer Lopes, Jan L Ceuppens, Stefaan W Van Gool.   

Abstract

Injection of dendritic cells (DC) pulsed with tumor antigens is a novel treatment strategy against malignancies, and aims to elicit anti-tumoral cell-mediated immune responses. We studied the in vitro proliferative responses and cytokine production in T cell cultures after 2 stimulations with autologous DC loaded with tumor lysates derived from glioblastoma multiforme (GBM) cells in the presence of recombinant interleukin (rIL)-6/rIL-12 in the first, and rIL-2/rIL-7 in the second stimulation. After the second stimulation, T cells were co-cultured with glioblastoma (GBM) cells and tumor growth suppression by T cells was assessed using a MTT assay. Although loaded DC induced a significant shift towards T helper cell type 1 (Th1) cytokine production as compared to unloaded DC, persistent interleukin (IL)-10 production by T cells both at the end of 2 stimulations with loaded DC and during the effector phase was also required for their tumor suppressive activity. A stronger glioma growth suppressive activity by T cells stimulated with tumor lysate-loaded DC than by control T cells, cultured with unloaded DC, was seen only if the relative IL-10 production after two stimulations with loaded DC was at least 40% of the IL-10 production after two stimulations with unloaded DC. If less than 40% IL-10 was produced in the experimental condition compared to the control condition, T cells also lost their tumor growth suppressive activity. Addition of rIL-10 during stimulation increased the suppressive activity on tumor cell viability and interferon (IFN)-gamma production by T cells that showed Th1 response upon stimulation with loaded DC. The data point towards the production of both IFN-gamma and IL-10 by responding effector T cells, and towards an immune modulatory rather than immune suppressive role of IL-10 to generate anti-tumoral effector T cells against GBM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361330     DOI: 10.1007/s11060-007-9362-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

Review 1.  Type 1 and type 2: a fundamental dichotomy for all T-cell subsets.

Authors:  L L Carter; R W Dutton
Journal:  Curr Opin Immunol       Date:  1996-06       Impact factor: 7.486

Review 2.  Pediatric supratentorial high-grade gliomas.

Authors:  Mandeep S Tamber; James T Rutka
Journal:  Neurosurg Focus       Date:  2003-02-15       Impact factor: 4.047

Review 3.  Mechanisms of interleukin-10-mediated immune suppression.

Authors:  C A Akdis; K Blaser
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

4.  Interferon-gamma inhibits growth and migration of A172 human glioblastoma cells.

Authors:  M M Knüpfer; H Knüpfer; V Jendrossek; S Van Gool; J E Wolff; E Keller
Journal:  Anticancer Res       Date:  2001 Nov-Dec       Impact factor: 2.480

5.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

Authors:  L M Liau; K L Black; R M Prins; S N Sykes; P L DiPatre; T F Cloughesy; D P Becker; J M Bronstein
Journal:  J Neurosurg       Date:  1999-06       Impact factor: 5.115

6.  Cytokine mediated regulation of interferon-gamma-induced IDO activation.

Authors:  C R MacKenzie; R G González; E Kniep; S Roch; W Däubener
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

7.  A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

Authors:  P van der Bruggen; J Bastin; T Gajewski; P G Coulie; P Boël; C De Smet; C Traversari; A Townsend; T Boon
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

8.  Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells.

Authors:  T Schüler; T Kammertoens; S Preiss; P Debs; N Noben-Trauth; T Blankenstein
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

9.  Altered immune responses in interleukin 10 transgenic mice.

Authors:  A Hagenbaugh; S Sharma; S M Dubinett; S H Wei; R Aranda; H Cheroutre; D J Fowell; S Binder; B Tsao; R M Locksley; K W Moore; M Kronenberg
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

10.  Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.

Authors:  L M Zheng; D M Ojcius; F Garaud; C Roth; E Maxwell; Z Li; H Rong; J Chen; X Y Wang; J J Catino; I King
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  12 in total

1.  Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Authors:  Hilko Ardon; Stefaan Van Gool; Isabel Spencer Lopes; Wim Maes; Raf Sciot; Guido Wilms; Philippe Demaerel; Patricia Bijttebier; Laurence Claes; Jan Goffin; Frank Van Calenbergh; Steven De Vleeschouwer
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

2.  High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Authors:  Heike Pohla; Alexander Buchner; Birgit Stadlbauer; Bernhard Frankenberger; Stefan Stevanovic; Steffen Walter; Ronald Frank; Tim Schwachula; Sven Olek; Joachim Kopp; Gerald Willimsky; Christian G Stief; Alfons Hofstetter; Antonio Pezzutto; Thomas Blankenstein; Ralph Oberneder; Dolores J Schendel
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

3.  Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.

Authors:  Catalina Lee-Chang; Aida Rashidi; Jason Miska; Peng Zhang; Katarzyna C Pituch; David Hou; Ting Xiao; Mariafausta Fischietti; Seong Jae Kang; Christina L Appin; Craig Horbinski; Leonidas C Platanias; Aurora Lopez-Rosas; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

Review 4.  Current state and future prospects of immunotherapy for glioma.

Authors:  Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 5.  Dendritic cell vaccines for brain tumors.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

6.  DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Authors:  Wim Maes; Georgina Galicia Rosas; Bert Verbinnen; Louis Boon; Steven De Vleeschouwer; Jan L Ceuppens; Stefaan W Van Gool
Journal:  Neuro Oncol       Date:  2009-03-31       Impact factor: 12.300

Review 7.  Brain Tumor Immunotherapy: What have We Learned so Far?

Authors:  Stefaan Willy Van Gool
Journal:  Front Oncol       Date:  2015-06-17       Impact factor: 6.244

8.  Genetic association between selected cytokine genes and glioblastoma in the Han Chinese population.

Authors:  Tianbo Jin; Xiaolan Li; Jiayi Zhang; Hong Wang; Tingting Geng; Gang Li; Guodong Gao; Chao Chen
Journal:  BMC Cancer       Date:  2013-05-12       Impact factor: 4.430

Review 9.  IL-10 in glioma.

Authors:  Samuel S Widodo; Marija Dinevska; Liam M Furst; Stanley S Stylli; Theo Mantamadiotis
Journal:  Br J Cancer       Date:  2021-08-04       Impact factor: 9.075

Review 10.  Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Authors:  Powell Perng; Michael Lim
Journal:  Front Oncol       Date:  2015-07-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.